RecruitingNCT04548817

Neurocutaneous Melanocytosis Registry

Prospective Registry of Patients With Neurocutaneous Melanocytosis (NCM) Including Cutaneous and CNS Involvement


Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

100 participants

Start Date

Sep 3, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

This study will involve collecting information about the regular medical care you receive for large cutaneous melanocytic nevi (LCMN) or neurocutaneous melanocytosis (NCM).


Eligibility

Plain Language Summary

Simplified for easier understanding

This registry is collecting information about patients with Neurocutaneous Melanocytosis (NCM) — a rare condition where abnormal pigment cells grow on the skin and/or in the brain and spinal cord — to better understand the disease and support future research. **You may be eligible if...** - You have a large congenital melanocytic nevus (LCMN) — a large dark birthmark — which may or may not have satellite lesions or abnormal hair growth - OR you have confirmed melanocyte overgrowth in the central nervous system (brain or spinal cord), even without a skin birthmark - Patients of any age can be included, including children - Deceased patients may also be included (with guardian consent, contacted at least 6 months after death) **You may NOT be eligible if...** - You do not have a large congenital melanocytic nevus or confirmed CNS melanocytosis - A parent or legal guardian is not available to provide consent for minor patients Talk to your doctor to see if this trial is right for you.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.


Locations(2)

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, United States

Boston Children's Hospital (Data Analysis Only)

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04548817